无容量
医学
索拉非尼
免疫疗法
免疫检查点
银耳霉素
瑞戈非尼
肝细胞癌
癌症研究
肿瘤科
易普利姆玛
封锁
免疫系统
癌症
内科学
免疫学
结直肠癌
受体
作者
Han Cheng,Guodong Sun,Hao Chen,Li Yu,Ze‐Guang Han,Yangbing Li,Peng Zhang,Luxi Yang,Yumin Li
出处
期刊:PubMed
日期:2019-01-01
卷期号:9 (8): 1536-1545
被引量:60
摘要
Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase inhibitors (TKIs), including sorafenib, lenvatinib, regorafenib and cabozantinib, have been widely utilized int the treatment of HCC. However, with tolerable adverse events and relative low survival time, neo or optimized therapies for advanced HCC are still urgently needed. New developed immune checkpoint inhibitors therapy have been first demonstrated effective in metastatic melanoma through against CTLA-4 or PD-1/PD-L1 to renew T cell effector function. Preclinical data indicated that interference with immune checkpoint molecules results in HCC growth suppression, suggesting it may bring hope to the HCC treatment. Several clinical trials applying monoclonal antibodies to immune checkpoint molecules demonstrated that immune checkpoint inhibitors are safe and enable durable antitumor activity in advanced HCC patients. Several published immunotherapy trials in HCC using Anti-CTLA-4 agents (tremelimumab) or anit-PD-1 agents (Nivolumab) have showed promising results, in which have similar response rate (15%-30%) and disease control rate with TKIs therapies. This article will review the on-going clinical trials associated with immune checkpoint molecules monotherapy or co, and then discuss the optimal scheme of immune checkpoint therapy for advanced HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI